303 related articles for article (PubMed ID: 36334015)
1. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
[TBL] [Abstract][Full Text] [Related]
2. Serum leucine-rich alpha-2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan.
Yasuda R; Arai K; Kudo T; Nambu R; Aomatsu T; Abe N; Kakiuchi T; Hashimoto K; Sogo T; Takahashi M; Etani Y; Kato K; Yamashita Y; Mitsuyama K; Mizuochi T
J Gastroenterol Hepatol; 2023 Jul; 38(7):1131-1139. PubMed ID: 36880154
[TBL] [Abstract][Full Text] [Related]
3. Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease.
Yoshida T; Shimodaira Y; Fukuda S; Watanabe N; Koizumi S; Matsuhashi T; Onochi K; Iijima K
Tohoku J Exp Med; 2022 Jul; 257(4):301-308. PubMed ID: 35598974
[TBL] [Abstract][Full Text] [Related]
4. Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease.
Ichimiya T; Kazama T; Ishigami K; Yokoyama Y; Hayashi Y; Takahashi S; Itoi T; Nakase H
PLoS One; 2023; 18(6):e0286415. PubMed ID: 37352151
[TBL] [Abstract][Full Text] [Related]
5. Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn's disease.
Abe I; Shiga H; Chiba H; Miyazawa T; Oomori S; Shimoyama Y; Moroi R; Kuroha M; Kakuta Y; Kinouchi Y; Masamune A
J Gastroenterol Hepatol; 2022 Sep; 37(9):1741-1748. PubMed ID: 35641439
[TBL] [Abstract][Full Text] [Related]
6. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
7. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
Shinzaki S; Matsuoka K; Tanaka H; Takeshima F; Kato S; Torisu T; Ohta Y; Watanabe K; Nakamura S; Yoshimura N; Kobayashi T; Shiotani A; Hirai F; Hiraoka S; Watanabe M; Matsuura M; Nishimoto S; Mizuno S; Iijima H; Takehara T; Naka T; Kanai T; Matsumoto T
J Gastroenterol; 2021 Jun; 56(6):560-569. PubMed ID: 33942166
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.
Yoshimura T; Mitsuyama K; Sakemi R; Takedatsu H; Yoshioka S; Kuwaki K; Mori A; Fukunaga S; Araki T; Morita M; Tsuruta K; Yamasaki H; Torimura T
Mediators Inflamm; 2021; 2021():8825374. PubMed ID: 33623482
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
Jusué V; Chaparro M; Gisbert JP
Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
[TBL] [Abstract][Full Text] [Related]
11. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease.
Yasutomi E; Inokuchi T; Hiraoka S; Takei K; Igawa S; Yamamoto S; Ohmori M; Oka S; Yamasaki Y; Kinugasa H; Takahara M; Harada K; Furukawa M; Itoshima K; Okada K; Otsuka F; Tanaka T; Mitsuhashi T; Kato J; Okada H
Sci Rep; 2021 May; 11(1):11086. PubMed ID: 34045529
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
[TBL] [Abstract][Full Text] [Related]
14. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.
Lin WC; Wong JM; Tung CC; Lin CP; Chou JW; Wang HY; Shieh MJ; Chang CH; Liu HH; Wei SC;
World J Gastroenterol; 2015 Dec; 21(48):13566-73. PubMed ID: 26730169
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease.
Kawamura T; Yamamura T; Nakamura M; Maeda K; Sawada T; Ishikawa E; Iida T; Mizutani Y; Ishikawa T; Kakushima N; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M
Inflamm Bowel Dis; 2023 Feb; 29(2):245-253. PubMed ID: 35436345
[TBL] [Abstract][Full Text] [Related]
16. Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.
Swaminathan A; Borichevsky GM; Edwards TS; Hirschfeld E; Mules TC; Frampton CMA; Day AS; Hampton MB; Kettle AJ; Gearry RB
J Crohns Colitis; 2022 Dec; 16(12):1862-1873. PubMed ID: 35803583
[TBL] [Abstract][Full Text] [Related]
17. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
Shinzaki S; Matsuoka K; Iijima H; Mizuno S; Serada S; Fujimoto M; Arai N; Koyama N; Morii E; Watanabe M; Hibi T; Kanai T; Takehara T; Naka T
J Crohns Colitis; 2017 Jan; 11(1):84-91. PubMed ID: 27466171
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
19. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
20. Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease.
Sakurai T; Saruta M
Digestion; 2023; 104(1):30-41. PubMed ID: 36404714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]